Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

Efficacy and Safety of Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.

Inclusion Criteria:

• Have completed the core CZOL446H2202 study
• Males or females between 1-17 years of age

Exclusion Criteria:

• Deformity or abnormality which would prevent spine bone density from being done
• Any surgical bone-lengthening procedure
• Any kidney diseases or abnormalities
• Low calcium or vitamin D levels in the blood

Other protocol-defined inclusion/exclusion criteria may apply.